Manipal Health Enterprises Ltd
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹590
Per ShareLot Size
25 Shares
Minimum Investment
₹14,750
Issue Size
₹9,275.22 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
10%
QIB Quota
75%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Manipal Health Enterprises Ltd
Business model, operations, and market positioning.
About the Company
We operate a pan-India network of multispecialty hospitals delivering a comprehensive range of care services from outpatient services to complex tertiary and quaternary interventions. As of September 30, 2025, we operated 38 hospitals (48 hospitals on a pro forma basis) with 10,761 licensed beds (12,367 licensed beds on a pro forma basis) across 14 states and union territories. We have the widest footprint in terms of presence of hospitals among private hospital chains in India as of September 30, 2025. For details, see "-Our Hospitals and Facilities" on page 238. We are the largest pan-India multispecialty hospital network by bed capacity and the second largest hospital chain by number of hospitals as of September 30, 2025 (Source: CRISIL Report). In November 2025, we commenced operations at our 49th hospital in Bengaluru (Karnataka), which increased our licensed bed capacity to 12,631 licensed beds as of December 31, 2025. For Fiscal 2025, we reported the second-highest revenue from operations of Rs.92,635.56 million (on a pro forma basis) among private hospital chains in India, and reported the third-highest revenue from operations of Rs.82,422.50 million, among private hospital chains in India.
Company History
The Company was originally incorporated in Bengaluru, Karnataka as `Manipal Health Enterprises Private Limited' as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated February 15, 2010, issued by the RoC. Subsequently, our Company was converted to a public limited company and the name of our Company was changed to Manipal Health Enterprises Limited pursuant to a resolution passed by our Board and by its Shareholders passed on November 8, 2025 and November 20, 2025, respectively and a fresh certificate of incorporation dated December 24, 2025 was issued by the Registrar of Companies, Central Processing Centre.
Growth Strategy
- Continue capitalizing growth opportunities in existing facilities and organic network expansion
- Strategic acquisitions to enter and consolidate market positions and improve access and patient care
- Leverage digital, AI and technology to extend patient reach and access, transform patient and clinician experiences, expand out-of-hospital care and continue to focus on operational excellence to drive efficiencies.
- Continue to attract, develop, and retain medical talent.
- Invest in advanced medical infrastructure and clinical innovations.
Promoter Holding (Pre-Issue)
81.86%
Promoter Holding (Post-Issue)
70.9%
Issue Type
Book Building
ISIN
INE459N01021
Financial Performance
Revenue, profit, and asset growth over the last three financial years.
Data presented in crores for FY20 to FY24.
Objects of the Issue
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offer of 157,233,715 equity shares of face value of Rs. 2 each ("Equity Shares") of Manipal Health Enterprises Limited ("Company" or "Issuer") for cash at a price of Rs. 590 per equity share (including a share premium of Rs. 588 per equity share) ("Offer Price") aggregating to Rs. 9275.22 Crores comprising a fresh issue of 135,619,881 equity shares of face value of Rs. 2 each aggregating to Rs. 8000.00 Crores by the company ("Fresh Issue") and an offer for sale of 21,613,834 equity shares of face value of Rs. 2 each aggregating to Rs. 1275.22 Crores by the selling shareholders, comprising an offer for sale of 10,808,861 equity shares of face value of Rs. 2 each aggregating to Rs. 637.72 Crores by Imperius Healthcare Investments Pte. Ltd., (the "Promoter Selling Shareholder"), 6,792,002 equity shares of face value of Rs. 2 each aggregating up Rs. 400.73 Crores by Manipal Education and Medical Group India Private Limited (the "Promoter Group Selling Shareholder"), 2,329,667 equity shares of face value of Rs. 2 each aggregating to Rs. 137.45 Crores by TPG SG Magazine Pte. Ltd., 792,494 equity shares of face value of Rs. 2 each aggregating to Rs. 46.76 Crores by Seventy Second Investment Company LLC, 405,791 equity shares of face value of Rs. 2 each aggregating to Rs. 23.94 Crores by Ammar SDN BHD, 264,556 equity shares of face value of Rs. 2 each aggregating to Rs. 15.61 Crores by Novo Holdings Invest Asia A/S, and 220,463 equity shares of face value of Rs. 2 each aggregating to Rs. 13.01 Crores by Phoenix Bear Investments, LLC, (collectively the "Investor Selling Shareholders") (the promoter selling shareholder, the promoter group selling shareholder and the investor selling shareholders collectively referred to as the "Selling Shareholders" and such equity shares offered by the selling shareholders ("Offered Shares") and such offer, "Offer For Sale", and together with the fresh issue, the "Offer"). This offer includes a reservation of up to 254,237 equity shares of face value of Rs. 2 each, aggregating up to Rs. 15 Crore (constituting up to [*]% of the post-offer paid-up equity share capital), for subscription by eligible employees (the "Employee Reservation Portion"). The company in consultation with the brlms, may offer a discount of Rs. 56 per equity share of face value of Rs. 2 each, to eligible employees bidding in the employee reservation portion ("Employee Discount"), subject to necessary approvals as may be required. The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer would constitute [*]% and [*]% of the post-offer paid-up equity share capital of the company, respectively. The company, in consultation with the brlms, may consider a pre-ipo placement of equity shares, as may be permitted under applicable law, at its discretion, aggregating up to Rs.1600.00 crores prior to filing of the ("pre-ipo placement"). The pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the brlms. If the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (regulation) Rules, 1957, as Amended. The pre-ipo placement, if undertaken, shall not exceed 20% of the size of the fresh issue. The utilisation of the proceeds raised pursuant to the pre-ipo placement will be done towards the proposed objects of the offer in compliance with applicable law. prior to the completion of the offer, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the pre-ipo placement, that there is no guarantee that the company may proceed with the offer or the offer may be successful and will result into listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if undertaken). Price Band: Rs. 590 per equity share of face value of Rs. 2 each. The floor price is 295 times the face value of the equity shares. Bids can be made for a minimum of 25 equity shares of face value of Rs. 2 each and in multiples of 25 equity shares of face value of Rs. 2 each thereafter. A discount of Rs. 56 per equity share is being offered to eligible employees bidding in the employee reservation portion.
*Subject to approvals and market conditions.
- India's largest multispecialty hospital group by bed capacity with pan-India presence and leadership in our three key regions.
- We are the only private hospital chain network in India with leadership in three metros (Bengaluru, Kolkata and Pune) with a balanced and diversified presence across metros and non-metros.
- Widely recognized brand and network of choice for patients, doctors and healthcare professionals.
- Advanced infrastructure and medical equipment, with a strong focus on clinical excellence.
- Track record of delivering industry leading growth with strong profitability and efficiency metrics.
- A substantial number of the company's hospitals is located in Karnataka. Its derived 46.40%, 51.55%, and 59.98%, of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively, from its hospitals in Karnataka. Any loss of business or disruption in the operations of these hospitals or geopolitical or policy changes in Karnataka could have a material adverse effect on the company's business, financial condition, results of operations, cash flows and prospects.
- The company primarily generates revenue by providing inpatient care at its hospitals. Any inability to maintain or improve the company's admissions and hospital occupancy rates could adversely affect its business, financial condition, results of operations, cash flows and prospects.
- The company derived 64.30%, 62.56% and 61.55% of its gross inpatient revenue from cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics, and renal sciences ("CONGO-R") specialties in Fiscals 2026, 2025 and 2024, respectively, and any negative changes in the demand for these specialties could adversely impact the company's business, results of operations and financial condition.
- A portion of the Net Proceeds is proposed to be utilized for repayment or prepayment of certain borrowings in the nature of Non-Convertible Debentures issued by one of the company's Subsidiaries to DBS Bank Ltd., which is the parent company of DBS Bank India Limited, which is deemed to be an "Associate" of Imperius Healthcare Investments Pte. Ltd. (one of its Promoters and Selling Shareholders) in terms of Regulation 21A of SEBI Merchant Bankers Regulations.
- Acquisitions, strategic investments, partnerships or alliances may be difficult to identify, acquires and integrate, and may adversely affect the company's business, financial condition, results of operations, cash flows and prospects.